AQST - CIK 0001398733
Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.55M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $44.55M | -22.6% |
| FY 2024 | $57.56M | +13.8% |
| FY 2023 | $50.58M | +6.1% |
| FY 2022 | $47.68M | -6.2% |
| FY 2021 | $50.83M | +10.9% |
| FY 2020 | $45.85M | -12.8% |
| FY 2019 | $52.61M | -22.0% |
| FY 2018 | $67.43M | +0.8% |
| FY 2017 |
Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.55M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Aquestive Therapeutics, Inc.'s revenue declined from $66.92M to $44.55M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $66.92M |
| - |